GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

IGC Pharma IGC · USD

Industrials · US listing · 🇺🇸 United States

Compare

0.20

+2.20%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

IGC Pharma annual report

Filed with the US Securities and Exchange Commission

10-K

The latest annual report covers the year to 31 Mar 2025, filed on 27 Jun 2025.

Read the 10-K on SEC.gov ↗

Five-year highlights

In USD.

FY2026FY2025FY2024FY2023FY2022
Revenue$1.2m$1.3m$1.3m$911,000$397,000
Operating income−$10.2m−$7.4m−$9.8m−$11.6m−$15.4m
Net income−$6.5m−$7.1m−$13.0m−$11.5m−$15.0m
Free cash flow−$6.1m−$5.3m−$5.7m−$7.7m−$8.2m
Total assets$9.2m$8.7m$9.9m$17.2m$26.8m
Shareholders' equity$6.1m$6.3m$7.3m$14.9m$23.9m

Revenue by business

Year to 31 Mar 2024

  • Plant and Cannabinoid [Member] $1.2m · 87.8%
  • Tolling/White labeling service [Member] $953,000 · 70.9%
  • Wellness and Lifestyle [Member] $228,000 · 17.0%
  • Legacy Infrastructure [Member] $164,000 · 12.2%
  • Construction [Member] $146,000 · 10.9%
  • Rental Income [Member] $18,000 · 1.3%

Revenue by region

Year to 31 Mar 2024

  • UNITED STATES $1.2m · 87.7%
  • INDIA $164,000 · 12.2%
  • COLOMBIA $2,000 · 0.1%

Filings

Newest first, from SEC EDGAR

Sources and methodology

Data on this tab
SEC EDGAR and our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.